Page 4 - Nasdaq Indp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq indp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Indp Today - Breaking & Trending Today

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors. ....

United States , Michael Newman , Louie Toma , Jules Abraham , Michaelj Newman , Indaptus Therapeutics Inc , Company Founder , Company Decoy , American Association For Cancer Research , American Association , Cancer Research , Chief Scientific Officer , Indaptu Chief Scientific Officer , Private Securities Litigation Reform , Annual Report , Relations Contact , Nasdaq Indp , Indaptus Therapeutics ,

Q2 2023 EPS Estimates for Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increased by Analyst

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) – Research analysts at HC Wainwright upped their Q2 2023 earnings per share (EPS) estimates for Indaptus Therapeutics in a research report issued on Monday, March 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.63) for the quarter, up […] ....

Indaptus Therapeutics Inc , Northern Trust Corp , Strategy Asset Managers , Renaissance Technologies , Vanguard Group Inc , Indaptus Therapeutics , Get Rating , Indaptus Therapeutic , Trust Corp , Street Corp , Asset Managers , Vanguard Group , Indaptus Therapeutics Daily , Nasdaq Indp , Earnings Estimates , Hc Wainwright ,

Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 182,100 shares, a growth of 569.5% from the May 15th total of 27,200 shares. Currently, 3.2% of the shares of the stock are short sold. Based on an average daily […] ....

Jeffreya Meckler , Northern Trust Corp , Geode Capital Management , Securities Exchange Commission , Indaptus Therapeutics Inc , Zacks Investment Research , Vanguard Group Inc , Millennium Management , Indaptus Therapeutics , Get Rating , Exchange Commission , Street Corp , Trust Corp , Capital Management , Nasdaq Indp ,

Brokerages Expect Indaptus Therapeutics, Inc. (NASDAQ:INDP) to Post -$0.43 EPS

Analysts predict that Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) will report earnings per share of ($0.43) for the current quarter, Zacks reports. Zero analysts have made estimates for Indaptus Therapeutics’ earnings. Indaptus Therapeutics posted earnings of ($5.53) per share in the same quarter last year, which would suggest a positive year over year growth […] ....

Northern Trust Corp , Geode Capital Management , Indaptus Therapeutics Inc , Zacks Investment Research , Marshall Wace , Citadel Advisors , Indaptus Therapeutics Company Profile Get Rating , Indaptus Therapeutics , Get Rating , Indaptus Therapeutic , Investment Research , Trust Corp , Street Corp , Therapeutics Company Profile , Nasdaq Indp ,

Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Down 38.3% in May

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 27,200 shares, a drop of 38.3% from the April 30th total of 44,100 shares. Currently, 0.5% of the shares of the company are sold […] ....

Northern Trust Corp , Marshall Wace , Geode Capital Management , Indaptus Therapeutics Inc , Zacks Investment Research , Citadel Advisors , Indaptus Therapeutics , Get Rating , Trust Corp , Street Corp , Investment Research , Nasdaq Indp ,